Mr. Chair, thank you to the member for that question.
On BA.2.75, indeed, BA.2.75.2 is the specific sublineage that we're monitoring. It's part of the group that I mentioned in response to the last question. The BA.2.75 and its sublineages currently represent 1.1% of the sequences detected in mid-September. It has stalled recently in Canada.
However, it still needs to be monitored, because BA.2.75.2 has been growing considerably faster than other BA.2.75 sublineages that we're monitoring. The vast majority of sequences in Canada at this point are still BA.5, but BA.5 has many different variations that we are monitoring, as I've said in my last report. The member is correct, in that one of the concerns is that is it able to evade potential prior immunity or monoclonal antibody treatment.
The good news is that we do have these bivalent vaccines. They are now on board. All of the vaccines so far, actually, have good impacts on severe outcomes.
As well, we have treatments like Paxlovid. That is not a monoclonal antibody treatment, and it is available for those at the highest risk.